Phase 1CompletedAge-related condition
Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease
Phase Ib Safety, Tolerability and Pharmacokinetic Study of Subcutaneously Administered HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease
- Sponsor
- Herantis Pharma Plc. (Industry)
- Enrolment
- 32 enrolled
- Conditions
- Parkinson Disease, Idiopathic
- Interventions
- HER-096; HER-096; Placebo
- Ages
- adults, older adults
- Registry
- NCT06659562
Full record on ClinicalTrials.gov
From the registry
In this clinical study, the safety and tolerability of HER-096 and the way the body interacts with the drug (pharmacokinetics) will be investigated. The clinical study consists of two parts. In Part 1, the drug HER-096 is given as a single dose to healthy volunteer subjects. In Part 2, HER-096 or placebo (physiological saline) is given as multiple doses during a 4-week period to patients with Parkinson´s disease. The doses are given as injections under the skin (subcutaneous injection).
Primary outcomes
- Treatment-Emergent Adverse Events (TEAEs)
- Physical Examination
- Vital Signs
- Laboratory safety assessments - Haematology
History
Last registry update
Study completion
Primary completion
Registered
Started